# US 2026/0117181 A1 · ERRalpha GENE KNOCKOUT ERYTHROID PROGENITOR CELLS AND METHODS OF ERYTHROID DIFFERENTIATION THEREOF

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0117181 A1
- Document ID: US20260117181A1
- Status: Published application
- Kind: A1
- Application number: 19/303,362
- Filed: 2025-08-19
- Published: 2026-04-30
- Earliest claimed: 2024-10-24
- Assignees: Pusan National University Industry-University Cooperation Foundation
- Applicants: Pusan National University Industry-University Cooperation Foundation
- Inventors: Dongjun Lee; Jiwon KIM; Hee Eun BAE; Hee Seon CHOI
- Web page: https://patentgrep.com/patent/US20260117181A1

## CPC

- C12N 5/0641: {Erythrocytes}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/86: Viral vectors
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2500/25: Insulin-transferrin; Insulin-transferrin-selenium
- C12N 2501/125: Stem cell factor [SCF], c-kit ligand [KL]
- C12N 2501/14: Erythropoietin [EPO]
- C12N 2501/39: Steroid hormones
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2510/00: Genetically modified cells
- C12N 2740/15041: Use of virus, viral particle or viral elements as a vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure relates to an ERRα gene-knockout erythroid progenitor cell and a method of differentiating the same into an erythrocyte, wherein it has been determined that ERRα gene-knockout cells, in which an ERRα gene is knocked out in erythroid progenitor cells, express erythroid differentiation markers at a higher rate and undergo erythroid differentiation more rapidly under erythroid differentiation conditions according to the present disclosure, such that the present disclosure provides a method that enables rapid differentiation of erythrocytes using ERRα gene-knockout erythroid progenitor cells.

## Claims

### Claim 1

A method for erythroid differentiation, the method comprising:
knocking out an estrogen-related receptor alpha (ERRα) gene in erythroid progenitor cells in vitro; and
culturing the ERRα gene-knockout erythroid progenitor cells in an erythroid differentiation medium to differentiate the erythroid progenitor cells into erythrocytes.

### Claim 2 (depends on 1)

The method of claim 1, wherein the erythroid progenitor cell is cultured in a medium comprising a stem cell factor (SCF), erythropoietin (EPO), doxycycline (DOX), and dexamethasone (DEX).

### Claim 3 (depends on 1)

The method of claim 1, wherein the knocking out of the ERRα gene comprises using the Clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system with shRNA to knock out the ERRα gene (GenBank ID: NC_000011.10) represented by SEQ ID NO: 1.

### Claim 4 (depends on 3)

The method of claim 3, wherein the ERRα shRNA is introduced into the erythroid progenitor cells by lentivirus.

### Claim 5 (depends on 1)

The method of claim 1, wherein the ERRα gene-knockout erythroid progenitor cells are selected from a medium comprising puromycin.

### Claim 6 (depends on 1)

The method of claim 1, wherein the knocking out of the ERRα gene comprises adding a lentivirus, which comprises an shRNA that complementarily binds to the ERRα gene represented by SEQ ID NO: 1, to the erythroid progenitor cells, followed by culture for 24 to 48 hours.

### Claim 7 (depends on 1)

The method of claim 1, wherein the differentiating into erythrocytes comprises:
(a) culturing the ERRα gene-knockout erythroid progenitor cells in a primary differentiation medium comprising erythropoietin (EPO), insulin, transferrin, doxycycline (DOX), and a stem cell factor (SCF) for 4 days;
(b) culturing the ERRα gene-knockout erythroid progenitor cells for 3 days in a secondary differentiation medium comprising erythropoietin (EPO), insulin, transferrin, and doxycycline (DOX); and
(c) culturing the ERRα gene-knockout erythroid progenitor cells in a third differentiation medium comprising erythropoietin (EPO), insulin, and transferrin.

### Claim 8 (depends on 1)

The method of claim 1, wherein the differentiating of the erythroid progenitor cells into erythrocytes is completed within 7 to 22 days.

### Claim 9 (depends on 1)

An erythrocyte differentiated by the method according to claim 1.
